- Home
- GERN vs LEU Comparison
GERN vs LEU Comparison
Compare GERN & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- LEU
- Stock Information
- Founded
- GERN 1990
- LEU 1998
- Country
- GERN United States
- LEU United States
- Employees
- GERN N/A
- LEU N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- GERN Health Care
- LEU Industrials
- Exchange
- GERN Nasdaq
- LEU Nasdaq
- Market Cap
- GERN 1.5B
- LEU 1.3B
- IPO Year
- GERN 1996
- LEU 1998
- Fundamental
- Price
- GERN $1.55
- LEU $62.35
- Analyst Decision
- GERN Buy
- LEU Buy
- Analyst Count
- GERN 11
- LEU 4
- Target Price
- GERN $5.80
- LEU $147.00
- AVG Volume (30 Days)
- GERN 14.9M
- LEU 586.8K
- Earning Date
- GERN 05-01-2025
- LEU 05-06-2025
- Dividend Yield
- GERN N/A
- LEU N/A
- EPS Growth
- GERN N/A
- LEU N/A
- EPS
- GERN N/A
- LEU 4.47
- Revenue
- GERN $76,994,000.00
- LEU $442,000,000.00
- Revenue This Year
- GERN $208.83
- LEU $2.45
- Revenue Next Year
- GERN $57.49
- LEU $17.65
- P/E Ratio
- GERN N/A
- LEU $14.82
- Revenue Growth
- GERN 32386.92
- LEU 38.04
- 52 Week Low
- GERN $1.46
- LEU $33.51
- 52 Week High
- GERN $5.34
- LEU $122.95
- Technical
- Relative Strength Index (RSI)
- GERN 31.37
- LEU 33.61
- Support Level
- GERN $1.63
- LEU $71.88
- Resistance Level
- GERN $1.89
- LEU $77.70
- Average True Range (ATR)
- GERN 0.11
- LEU 4.34
- MACD
- GERN 0.03
- LEU -0.53
- Stochastic Oscillator
- GERN 0.37
- LEU 4.34
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.